Cytokine derived treatment with reduced vascular leak syndrome
US11401312B2 · kind B2 · utility
0Cited by
26References
28Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 22, 2014 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Apr 22, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.